...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Retina >Reducing the risk of endophthalmitis following intravitreal injections.
【24h】

Reducing the risk of endophthalmitis following intravitreal injections.

机译：减少玻璃体内注射后眼内炎的风险。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Intravitreal injection was introduced by Ohm in 1911 as a technique to introduce air for retinal tamponade and repair of retinal detachment. Intravitreal administration of pharmacotherapies dates to the mid-1940s with the use of penicillin to treat endophthalmitis. Since that time, use of the intravitreal injection technique has steadily increased, with its usage being focused primarily on the treatment of retinal detachment,endophthalmitis, and cytomegalovirus (CMV) retinitis. The increasing confidence in the efficacy and safety of intravitreal injections, in conjunction with the development of additional pharmacotherapies, has led to a recent rapid increase in the use of this technique for the administration of various inhibitors of vascular endothelial growth factor (e.g., ranibizumab, pegaptanib sodium, bevaci-zumab) for age-related macular degeneration (AMD) and diabetic retinopathy, and intravitreal tri-amcinolone for macular edema associated with a variety of conditions, such as diabetic retinopathy, central retinal vein occlusion, uveitis, birdshot retinochoroidopathy, and idiopathic cystoid macular edema.
机译：玻璃体内注射是Ohm在1911年提出的，它是一种为视网膜填塞和修复视网膜脱离引入空气的技术。玻璃体内药物治疗始于1940年代中期，当时使用青霉素治疗眼内炎。从那时起，玻璃体内注射技术的使用稳步增长，其应用主要集中在视网膜脱离，眼内炎和巨细胞病毒（CMV）视网膜炎的治疗上。随着玻璃体内注射的有效性和安全性的增强，以及开发新的药物治疗方法，人们对这种技术的使用迅速增加，最近该技术用于管理多种血管内皮生长因子抑制剂（如兰尼单抗，哌加他尼钠，贝伐单抗（bevaci-zumab）用于治疗老年性黄斑变性（AMD）和糖尿病性视网膜病变，玻璃体内注射三安西洛酮治疗与多种疾病相关的黄斑水肿，例如糖尿病性视网膜病变，视网膜中央静脉阻塞，葡萄膜炎，鸟状视网膜脉络膜病变，和特发性囊样黄斑水肿。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号